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DoxorubicinInsufﬁcient drug delivery into tumor cells limits the therapeutic efﬁcacy of chemotherapy. Co-delivery of
liposome-encapsulated drug and synthetic short-chain glycosphingolipids (SC-GSLs) signiﬁcantly improved
drug bioavailability by enhancing intracellular drug uptake. Investigating the mechanisms underlying this SC-
GSL-mediated drug uptake enhancement is the aim of this study. Fluorescence microscopy was used to visualize
the cell membrane lipid transfer intracellular fate of ﬂuorescently labeled C6-NBD-GalCer incorporated in
liposomes in tumor and non-tumor cells. Additionally click chemistry was applied to image and quantify native
SC-GSLs in tumor and non-tumor cell membranes. SC-GSL-mediated ﬂip-ﬂop was investigated in model mem-
branes to conﬁrm membrane-incorporation of SC-GSL and its effect on membrane remodeling. SC-GSL enriched
liposomes containing doxorubicin (Dox) were incubated at 4 °C and 37 °C and intracellular drug uptake was
studied in comparison to standard liposomes and free Dox.
SC-GSL transfer to the cell membrane was independent of liposomal uptake and the majority of the transferred
lipid remained in the plasmamembrane. The transfer of SC-GSL was tumor cell-speciﬁc and induced membrane
rearrangement as evidenced by a transbilayerﬂip-ﬂop of pyrene-SM. However, pore formationwasmeasured, as
leakage of hydrophilic ﬂuorescent probes was not observed. Moreover, drug uptake appeared to bemediated by
SC-GSLs. SC-GSLs enhanced the interaction of doxorubicin (Dox) with the outer leaﬂet of the plasmamembrane
of tumor cells at 4 °C. Our results demonstrate that SC-GSLs preferentially insert into tumor cell plasma
membranes enhancing cell intrinsic capacity to translocate amphiphilic drugs such as Dox across themembrane
via a biophysical process.
© 2015 Elsevier B.V. All rights reserved.Targeting Group, Laboratory
logy, Department of Surgery,
Box 2040, The Netherlands.
ofísica, Centro Mixto Consejo
el País Vasco/Euskal Herriko
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Ineffective outcome of chemotherapy is often due to dose-limiting
toxic side effects of free drug and to reduced drug bioavailability in
tumor cells. Liposomal drug carrier technology is extensively described
as an effectivemeans to prevent drug toxicity byminimizing drug inter-
action with healthy tissue [1–3]. Caelyx® or Doxil®, a formulation of
doxorubicin (Dox) encapsulated in PEGylated, 85–100 nm liposomes
(PLD) [4,5] is approved by EMA in Europe and by FDA in USA, for treat-
ment of AIDS-related Kaposi's sarcoma [6], refractory ovarian cancer [7],
myeloma [8] and metastatic breast cancer [6,9]. Although PLD accumu-
lates in tumor due to its favorable pharmacokinetic proﬁle and small
particle size [10], its high stability prevents optimal drug accumulation
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issue limiting its therapeutic efﬁcacy [2,13]. A novel approach to
enhance intracellular drug delivery in tumor cells was developed
and involves insertion of short-chain glycosphingolipids (SC-GSLs),
like C8-glucosylceramide (C8-GlcCer) or C8-galactosylceramide (C8-
GalCer) in the tumor cell membrane, increasing its permeability to
various anti-cancer drugs [14]. Co-delivery of SC-GSLs and drugs to
tumor cells using liposomes as a nanocarrier caused higher levels of
intracellular drug delivery speciﬁcally in tumor cells [15–18]. Themech-
anism underlying this SC-GSL mediated drug uptake enhancement and
its preference for tumor cells is the subject of this study.
Sphingolipids contain a sphingosine backbone where the functional
amino group at position C2 is acylated with a fatty acid (Fig. 1). One of
the most investigated sphingolipids, ceramide has a free functional
hydroxy group (−OH) at position C1, whereas in more complex
sphingolipids this position is linked to a polar head group. In the partic-
ular case of GSLs, the head group corresponds to a sugar residue (i.e.
glucose or galactose, among others). It has been described that long-
chain ceramides, but not short-chain, have membrane remodeling
properties when externally added or in situ generated in model mem-
branes [19,20]. For instances, ceramides induce transbilayer lipid
motion and increase membrane permeability in LUVs. Generation of
non-lamellar structures by ceramide creates transitory lipid-packaging
defects between lamellar and non-lamellar phases that account for the
lipid scrambling and membrane permeability effects observed. In addi-
tion, it has been reported that both short (C2) and long-chain (C16)
ceramides spontaneously form large stable pores in the outermitochon-
drial membrane contributing to cytochrome c release during initiation
of apoptosis [21]. Spontaneous formation of ceramide channels occurs
by lateral segregation of ceramide chains parallel to the plane of the
membrane with channel diameters of 0.8 nm for short-chain and up
to 11 nm for long-chain ceramides [21]. Further, Samanta et al. were
able to visualize C16-ceramide channels in a phospholipid membrane
by transmission electron microscopy [22]. These channels consisted of
columns of four to six ceramides H-bonded via amide groups and
arranged as staves in either a parallel or anti-parallel manner. Differ-
ences in the biophysical interactions between ceramides and phospho-
lipids are described to be dependent on the N-acyl chain length and the
intra- and intermolecular hydrogen bonds between sphingolipids and
surrounding lipids and lead to the formation of speciﬁc membrane
domains, lipid sorting and create signaling platforms [20,23]. Yet, for
SC-GSLs such as C8-GlcCer or C8-GalCer little is known about possible
mechanisms for domain formation and their role in enhancing drug
transport. It is also known that C6-ceramide does not enhance
intracellular Dox uptake [14,17] which points to the effect of the GSLFig. 1.Molecular structures of ceramide and short-chain glycosphingolipids (C8-glucoshydrophilic head group, such as C8-GlcCer or C8-GalCer, in the proper-
ties of short-chain GSLs as drug uptake enhancers.
In the present study, we aim at investigating the molecular mecha-
nisms underlying SC-GSL- mediated cellular drug uptake and to study
the cell type speciﬁcity of such mechanisms. To this end, the cellular
fate of liposomes and SC-GSLs is investigated by confocal microscopy
usingﬂuorescently labeled SC-GSL (C6-NBD-GalCer) and a stable liposo-
mal bilayer marker DiD, a lipophilic tracer with markedly red-shifted
ﬂuorescence excitation and emission spectra. Studies are performed in
tumor cells and normal cells to determine a possible preference for
SC-GSL transfer to tumor cells. In addition, post-treatment click chemis-
try is applied in order to disturb as little as possible the original molec-
ular structure of the lipid (C8-GlcCer or C8-GalCer) and its incorporation
into cell membranes is imaged by microscopy and quantiﬁed by TLC.
Finally new insights on SC-GSL mechanism of action as Dox uptake
enhancers to tumor cells are studied at 4 °C and biophysical features
of SC-GSLs are investigated using model membrane systems, due to
the technical difﬁculties of investigating these molecular issues in vivo.2. Materials and methods
2.1. Materials
Hydrogenated soy phosphatidylcholine (HSPC) and distearylphos-
phatidylethanolamine (DSPE)-PEG2000 were from Lipoid (Ludwigshaven,
Germany). Short-chain glycosphingolipids, C8 glucosyl(β) ceramide
(d18:1/8:0) D-glucosyl-β-1,1′ N-octanoyl-D-erythro-sphingosine (C8-
GlcCer), C8 galactosyl(β) ceramide (d18:1/8:0) D-galactosyl-β-1,1′ N-
octanoyl-D-erythro-sphingosine (C8-GalCer), C6-NBD galactosyl ceramide
N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-galactosyl-
β1-1′-sphingosine, egg-phosphatidylcholine (PC), phosphatidylethanol-
amine (PE), egg-sphingomyelin, liver phosphatidylinositol and brain PS
were purchased from Avanti Polar Lipids (Alabaster, AL, USA) and the
lipophilic tracer DiD (C67H103ClN2O3S) from Invitrogen, Carlsbad, USA.
Polycarbonate ﬁlters were from Northern Lipids (Vancouver, BC,
Canada) and PD-10 Sephadex columns were from GE Healthcare
(Diegem, Belgium). Cholesterol, Hepes (2-[4-(2-hydroxyethyl)-
piperazin-1-yl] ethanesulfonic acid). Hoechst was from Molecular
Probes (Leiden, The Netherlands). PBS was from Boom and FACS ﬂow
ﬂuid from BD Biosciences. Dox-HCl (Dox) was from Pharmachemie
(Haarlem, The Netherlands). Cholesterol (Chol) and Hepes (2-[4-(2-
hydroxyethyl)piperazin-1-yl] ethanesulfonic acid) were from SigmaAl-
drich (Zwijndrecht, The Netherlands). Pyrenebutyroyl-sphingomyelin
(pyr-SM) was synthesized as described in Contreras et al. [24].yl and C8-galactosyl). Molecular structures were design by Chem Draw Ultra 8.02.
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Standard and SC-GSL-enriched liposomes were formulated of HSPC/
cholesterol/ DSPE-PEG2000 in amolar ratio of 1.85:1:0.15. To themixture
of lipids, 0.1 mol of SC-GSL was added per mole of the total amount of
lipid (including cholesterol).
Liposomes of 85–100 nm in diameter were prepared by lipid ﬁlm
hydration and extrusion method using a thermobarrel extruder, North-
ern Lipids, Vancouver, Canada at 65 °C [24].
Lipids were dissolved in chloroform-methanol 9:1 (v/v) mixed
and a lipid ﬁlm was created under a reduced pressure on a rotary
evaporator and subsequently dried under a stream of nitrogen.
Finally, lipid ﬁlm was hydrated by 135 mM NaCl, 10 mM Hepes
buffer, pH 7.4 and liposomes were sized by sequential extrusion
through 100, 80, and 50 nm polycarbonate ﬁlters (Northern Lipids,
Vancouver, Canada).
Fluorescent labeled liposomes and ﬂuorescently labeled SC-GSL
liposomeswere prepared using the lipophilic tracer DiD, withmarkedly
red-shifted ﬂuorescence excitation and emission spectra (Invitrogen,
Carlsbad, USA) and C6-NBD galactosyl ceramide at 0.25 mol% of total
amount of lipids. For ﬂuorescently labeled SC-GSL liposomes,
0.25 mol% of C6-NBD-GalCer is added to the SC-GSL liposomes, already
containing 0.1 mol% of the respective SC-GSLs.
Hydration of the lipid ﬁlm with (NH4)2SO4 allowed loading of
liposomes with Dox by a transmembrane ammonium sulfate gradient.
Liposomes were loaded with Dox in a drug to phospholipid ratio of
0.1:1 (w/w) for 1 h at 65 °C [31]. Non-encapsulated Dox was removed
by ultracentrifugation at 29,000 rpm for 1 h at 4 °C in a Beckman
ultracentrifuge (Ti50.2 rotor). The liposome pellet was resuspended in
a Hepes buffer (135 mMNaCl, 10 mMHepes, pH 7.4). Size and polydis-
persity index (pdi) were determined at 25 °C by light scattering using a
Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). Lipid concen-
tration was measured by phosphate assay [25].
2.3. Large unilamellar liposome’s (LUV's) formulation
Large unilamellar liposome's (LUV's) mimicking plasma membrane
lipid composition was composed of 17.5% (mol) PC, 5% (mol) PS, 5%
(mol) PI, 10% (mol) PE, 50% (mol) Chol and 12.5% (mol) Egg- SM and
formulated as described elsewhere [26]. Lipids that were dissolved in
chloroform:methanol 2:1 (v/v) at the desired molar ratio and lipidic
mixture were dried under a stream of nitrogen. To eliminate remaining
traces of organic solvent, lipid mixture was placed in an exicator for
30 min under a vacuum. Resuspension of lipids was performed in a
Hepes buffer (5 M KOH, 100 mM Hepes, pH 7.4), and then they were
vigorously shaken with a vortex mixer to form multilamellar vesicles.
The liposome suspension was frozen and thawed for 10 cycles. A single
freeze–thaw cycle consisted of freezing for 2 min at liquid nitrogen
temperature (−196 °C) and thawing for 5 min in a water bath at
50 °C. Liposomes were extruded by 10 passages through two ﬁlters of
100 nm (Nucleopore, Pleasanton CA) at room temperature. LUVs were
kept on ice and used immediately after preparation.
2.4. Cell culture
All tumor cell lines (BLM melanoma, MDAMB-231 and SKBR-3
breast carcinoma, HeLa cervix carcinoma) were cultured in Dulbecco's
modiﬁed Eagle medium, supplemented with 10% fetal calf serum and
4 mM L-glutamine. HUVEC was isolated by collagenase digestion and
cultured in a HUVEC medium containing human endothelial serum-
free medium (Invitrogen), 20% heat-inactivated newborn calf serum
(Cambrex), 10% heat-inactivated human serum (Cambrex), 20 ng/ml
human recombinant epidermal basic ﬁbroblast growth factor
(Peprotech EC Ltd) and 100 ng/ml human recombinant epidermal
growth factor (Peprotech EC Ltd.) in ﬁbronectin (Roche Diagnostics)
coated ﬂasks. Fibroblasts (3T3) were cultured in a Dulbecco's modiﬁedEagle medium containing nutrient mixture F12, supplemented with
10% fetal calf serum and 4 mM L-glutamine. All serum supplements
were heat-inactivated at 56 °C for 30 min. Cells were subcultured
twice a week by trypsinization when a cell conﬂuence of 80–90% was
reached, and maintained in a water saturated atmosphere of 5% CO2 at
37 °C. Tumor cellswere seeded on a coating of 0.1% collagen (Invitrogen,
Carlsbad, USA) in a culturemediumandHUVECwas seeded on a coating
of 1mg/ml ﬁbronectin in PBS (Roche, Rotkreuz, Switzerland) for micro-
scopic imaging.2.5. Liposomal, SC-GSL and drug fate studied by confocal microscopy
Laser scanning confocalmicroscopy (Zeiss LSM510META)was used
to study the in vitro fate of ﬂuorescently labeled liposomes with DiD or
ﬂuorescently labeled SC-GSL (C6-NBD-GalCer) in SKBR3 cell after 2 h at
37 °C. C6-NBD-GalCer was excited with the 488 nm line from an Argon
ion laser, and emissions were detected between 505 nm and 550 nm.
Dox was excited with a 543 nm helium–neon laser. Dox emissions
were detected between 560 and 615 nm. The lipophilic tracer for
liposomes, DiD was excited with a 633 nm helium–neon laser and
near infrared emission was detected with a longpass 650 nm ﬁlter.
Plasma membrane was stained by WGA 488 (wheat germ agglutinin
from Invitrogen, Massachusetts, USA) to study co-localization of lipo-
somes. The LysoTracker® Red DND-99 (Invitrogen, Carlsbad, USA) was
incubated with cells in a concentration of 50 nM for 1 h at 37 °C. The
dye was excited with 543 nm and emission was detected with a
bandpass ﬁlter from 585 to 615 nm. Cells were imaged with a 63×
planachromat oil (n.a. 1.4) objective lens.
For confocal experiments, 1 ∗ 105 cells were seeded on glass cover
slides one day prior to imaging. Fluorescence intensity was quantiﬁed
by ImageJ by separating two classes of ﬂuorescence intensity (green as
low and red as higher intensity) applying a high threshold to image
the highest class intensity and membrane signal was selected and a
Gaussian blur distribution after which the signal is split into 3 classes,
background, low and high signals. Cells were imaged with a 63× plan-
apochromat oil (n.a. 1.4) objective lens.
To address the question of possible SC-GSL internalization, live cell
microscopywas performed in ascending focal planes in BLM,melanoma
cells. Cells were incubated with C6-NBD-GalCer liposomes and ﬂuores-
cence was detected using a Zeiss ELYRA PS1 microscope equipped
with a LSM 780 scanhead with high sensitivity GAsP detectors and
excited with the 488 nm line from an argon ion laser, with emissions
between 505 nm and 550 nm.
For time-lapse experiments, 10 positions on a slide were selected,
and images were taken every 15 min in 4 focal planes for up to 14 h.
The 633 nm He–Ne laser line was used for autofocus adjustments. In
addition, quantiﬁcation of cell-associated ﬂuorescent lipid analogue
using ImageJ software, yielded a 3 fold higher amount of ﬂuorescence
from C6-NBD-GalCer enriched liposomes measured in the cell mem-
brane of BLM,melanoma cells versusHUVEC, endothelial and 3T3, ﬁbro-
blasts. Themean ﬂuorescence intensity of a number of cells in each ﬁeld
of view was considered and subtracted from the background ﬂuores-
cence, which was the same in all images of all cell lines studied. A
mask was made as a thresholded area of a Gaussian blur image and
was applied to select the cell membrane of the cells. Mean ﬂuorescence
intensities are compared to tumor and non-tumor cell membranes in
time.
For confocal microscopy experiments at 4 °C, precooled cells were
treated with a 40 μM Dox in a form of free drug, standard liposomes
or 10% (mol) C8-GalCer enriched liposomes diluted in a cold culture
medium and incubated for 2 h at 4 °C. Cells were imaged before and
after washingwith a cold culturemedium. Cells were kept on ice during
experimental handling. Subsequently cells were further incubated for
2 h at 37 °C and 5% CO2 andwere imaged again before and afterwashing
with a culture medium.
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A clickable C8-GlcCer or C8-GalCer named as cC8-GlcCer and cC8-
GalCer, respectively, containing a ω-terminal alkyne in the fatty
acid was synthesized as described by Thiele et al. [25]. Addition of
the ω-terminal alkyne maintains the original chemical properties
of C8-GlcCer or C8-GalCer and allows the lipid detection by click
chemistry with an azide-labeled ﬂuorophore to localize and quantify
the respective SC-GSLs transferred to the cell. The alkyne group is
accessible to the azide once the lipid is inserted in the cell. Non-
inserted lipid is washed off before ﬁxation and labeling. To
determine optimal lipid analogue concentration and incubation
time, 105 HeLa cells were seeded in a 3.5 cm glass bottom dishes.
After the treatment with 40 μM of C8-GlcCer in ethanol/de-
lipidated medium, cells were incubated for 1 h or 2 h. In parallel,
cells were treated with 10 μM, 20 μM and 40 μM for 2 h at 37 °C,
and 5% CO2.
To determine SC-GSL transfer preferentially to tumor cells, BLM
melanoma and MDAMB, breast carcinoma cells were treated with
10 μM cC8-GlcCer or 10 μM cC8-GalCer in free form and 100 μM cC8-
GlcCer co-inserted in liposomes. Non-tumor cells 3T3, ﬁbroblasts were
treated with the same lipid concentrations as tumor cells. Cells were
washed twice in PBS and ﬁxed at RT for 10 min with 4% PFA, sucrose
and 4mMEDTA in PBS 4%. After ﬁxation, click chemistrywas performed
for 1 h at RT by adding amixture of 0.1M ascorbic acid, 1mMCuSO4 and
5 μMCy3-azide in 1mMTris–HCl pH 8. Control cells were treated in the
absence of CuSO4 that catalyze the click chemistry reaction. To localize
the lipid in the cell by ﬂuorescence microscopy, additional nuclear and
plasma membrane staining were performed with Hoescht (Molecular
Probes, Leiden, The Netherlands) andWGA 488 (wheat germ agglutinin
from Invitrogen,Massachusetts, USA), respectively. For SC-GSL quantiﬁ-
cation, cells were scraped and collected in 300 μl of PBS and centrifuged
at 6500 rpm for 5min at RT. Lipid extraction fromequal amounts of cells
and quantiﬁcation were performed as described in Thiele et al. [25].
Fluorescence images were acquired with a digital UV Chromato-Vue
cabinet (UVP, LLC).2.7. Transbilayer redistribution of pyrene-SM by SC-GSL
The extent of a transbilayer lipidmotion orﬂip-ﬂopwasmeasured in
LUVs composed of 17,5 mol% PC; 5 mol% PS; 5 mol% PI; 10 mol% PE;
50mol% Chol; and 12.5 mol% SM [26], by a method described byMüller
et al. [27]. This method consists of an asymmetric incorporation of a
pyreneﬂuorescent SM analogue (pyr-SM) inserted into the outer leaﬂet
of the membrane and a further dilution of the probe within the inner
and outer leaﬂets of the membrane upon a transbilayer redistribution
induced by SC-GSL membrane interaction. pyr-SM can be present in
the form of excimers (IE) when in high concentrations in the outer leaf-
let or monomers (IM) upon dilution of the probe to the inner leaﬂet of
the cytoplasmic membrane displaying different emissions at 465 nm
or 395 nm, respectively. Redistribution of pyr-SM from the outer to
the inner leaﬂet can be followed by a decrease of the excimer and an
increase in the monomer ﬂuorescence, decreasing the ratio IE/IM. The
transbilayer movement of pyr-SM in pure phospholipid vesicles is
described as very slow causing a constant IE/IM. Experiments were
performed at 37 °C in a spectroﬂuorometer AMINCO Bowman Series2.
Lipid concentration was 300 μM for LUVs to which 15 μM of pyr-SM
was added and incubated for 10 min at 37 °C prior to an addition of
15 μMof SC-GSL (C8-GlcCer or C8-GalCer and cC8-GlcCer or cC8-GalCer).
Immediately after pyr-SM incorporation in the outer leaﬂet of the
membrane, before any redistribution, IE/IM was set to 1. SC-GSL-
induced ﬂip-ﬂop is represented by IE/IM ratio of pyr-SMupon incorpora-
tion of SC-GSL into the outer leaﬂet of the membrane. Control
experiments were performed by adding ethanol, which was used as
vehicle to deliver SC-GSL.2.8. Leakage assay
Leakage of vesicular 8-aminonaphtalene-1,3,6-trisulfonate (ANTS)/
p-xylene bispyridinium bromide (DPX) was assayed, as explained by
Ellens et al. [28]. ANTS and DPX are water soluble anion/cation
ﬂuorophore quencher pair. ANTS ﬂuorescence in the liposome (plasma
membrane like LUVs) is quenched by collisional energy transfer to DPX.
When both ANTS and DPX are trapped in the lumen of a vesicle, they
exist in the form of a non-ﬂuorescent complex. When vesicle efﬂux
occurs, ANTS and DPX become diluted, the complex dissociates and
free ANTS emits ﬂuorescence. ANTS ﬂuorescence spectrum has an exci-
tationmaximum at 350 nmand an emissionmaximum at 530 nm. A cut
of ﬁlter of 450 nm was placed between the sample and the emission
monochromator to avoid scattering interferences. Liposomes were
prepared as described in Section 2.2. Non-encapsulated ANTS–DPX
complex is removed by passing the liposomes through a Sephadex G-
75 column. LUVSwere prepared freshly for each experiment. A spectro-
ﬂuorimeter Aminco Bowman Series 2 with a ﬂuorescence set at 355 nm
for excitation and 520 nm for emission in the presence of a ﬁlter of
450 nm to eliminate possible noise from the presence of liposomes,
was used to measure differences in the ﬂuorescence of ANTS–DPX
complex under constant mixing at 37 °C. The basal signal of ﬂuores-
cence was set to 0% before adding 15 μM of C8-GlcCer or C8-GalCer to
0.3 mM of the LUV's suspension. The ﬂuorescence for 100% release
was set after solubilizing liposomal membrane by adding Triton X-100
(10 mM ﬁnal concentration in the cuvette).
2.9. Intracellular drug uptake by ﬂow cytometry
Intracellular Dox levels in tumor BLMmelanomaand non-tumor 3T3
ﬁbroblasts were measured by ﬂow cytometry. Cells were seeded on a
ﬂat bottom 24 well plate at a ﬁnal concentration of 6 × 104 cells/well.
After 24 h at 37 °C, 5% CO2, cells were treated with 10 μM Dox in the
form of standard liposomes containing doxorubicin (Dox), C8-GlcCer
or C8-GalCer enriched liposomes diluted in the respective culture medi-
um. After 24 h treatment, cells were washed twice with PBS to remove
free drug and liposomes and cells were harvested by trypsinization. Cell
suspensions were resuspended in a FACS buffer (168 mg EDTA, 2,5 mg
BSA, 5 ml 10% NaN3 in PBS). Cell suspension was centrifuged at
400 rcf at 4 °C for 5 min. Cell pellets were resuspended in a 200 μl
FACS buffer containing the FarRed (L10120) LIVE/DEAD® dead cell
stain (Invitrogen, Carlsbad, USA) in a 1:1000 dilution. After 30 min at
RT, cells were analyzed by ﬂow cytometry (FACSCalibur, BD Biosci-
ences). Healthy cells were selected by size (forward scatter), shape
(sideward scatter) and viability (LIVE/DEAD stain, detected in FL4
channel, P653–669 nm). Cellular Dox uptake was measured by the
ﬂuorescent signal detected in the FL2 channel (BP 564–606 nm) after
excitation with a 488 nm laser. Cell count was set to 10,000 cells.
CellQuest™ software was used to analyze data.
2.10. Statistics
Data were analyzed using GraphPad Prism 5 software. Results of
two-tailed, unpaired t-test are indicated by: not signiﬁcant (ns)
(p N 0.05), * (p b 0.05), ** (p b 0.01), and ***(p b 0.001).
3. Results
3.1. Liposome characterization
Dox-loaded or empty liposomes with and without SC-GSLs were
prepared and characterized. Liposomes were obtained with sizes
between 85 and 95 nm, a polydispersity index (pdi) of b0.1 and Dox-
loading efﬁciency of N80%. Values for liposome size and pdi before
(empty-L) and after loading with Dox, drug concentration, loading
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are represented in Table 1.
3.2. SC-GSL transfer to cell membrane
SC-GSLs are described to enhance intracellular drug uptake from
liposomes into tumor cells [15,17,18,29]. To investigate the behavior
of SC-GSLs incorporated in liposomal bilayer when it contacts tumor
cell membranes, live cell imaging was performed in SKBR3 cells. After
2 h incubation at 37 °C with ﬂuorescently C6-NBD-GalCer labeled
liposomes (Fig. 2A), SC-GSLs were inserted throughout the tumor cell
plasma membrane. Within the plasma membrane, SC-GSLs tended to
accumulate in distinct areas with ﬁlopodia or lamellopodia like cellular
protrusions (Fig. 2B). Those membrane modiﬁcations were observed
once liposomes get in close contact with the plasma membrane
(Supplemental Fig. 1), which supports SC-GSL transfer from liposomes
to the plasma membrane [29].
Intracellular SC-GSL uptake was minor in comparison to the high
levels of lipid in the cell membrane. In the cytoplasm, SC-GSL ﬂuores-
cence intensities varied between 0 and 2000 AU. In contrast, lipid
ﬂuorescence reached a maximum intensity of 15,000 AU in the cell
membrane (Fig. 2B). An illustration of the transfer of ﬂuorescently
labeled C6-NBD-GalCer from liposomes in suspension (green) to the
cell membrane is presented in Movie 1. The massive accumulation of
the lipid in the cell membrane (red) is observed to occur in irregular
structures that surrounded the cell surface in contrast to a low lipid
concentration associated with liposomes in medium (green).
3.3. SC-GSL insertion into cell membrane is reversible
Next, we investigated a putative reversible mechanism of SC-GSL
insertion into cellular membranes. To this end, ascending focal planes
with a slide interval of 0.4 μm of BLM cells treated with ﬂuorescently
C6-NBD-GalCer labeled liposomes for 2 h at 37 °C was performed
(Fig. 3, middle panel). A massive lipid accumulation in the cell
membrane with a higher incidence in speciﬁc areas was observed. Con-
trol BLM cells without SC-GSL treatment (left panel) showed some
intracellular autoﬂuorescent signal. Intensive washing of SC-GSL-
liposome-treated cells with cold-PBS could remove a major part of the
SC-GSL from the membrane (right panel) pointing to a reversible
membrane interaction in the outer monolayer of the cell membrane.
After washing, some SC-GSL ﬂuorescence remained associated with
cells.
3.4. Cellular fate of SC-GSLs and liposome
To unravel the mechanism of action of SC-GSLs as cellular drug
uptake enhancers [17,18,29], we monitored the intracellular fate of
ﬂuorescently labeled liposomes in SKBR3 cells in relation to the SC-
GSL ﬂuorescent (Fig. 4). Dual labeled liposomes were used containing
the blue lipophilic tracer DiD as a stable marker for the liposomal
phospholipid bilayer and the green ﬂuorescent lipid analogue C6-NBD-
GalCer as SC-GSL marker. After 2 h incubation at 37 °C, liposomal nano-
particles (DiD, blue) remained solely outside the cell, whereas SC-GSL
(C6-NBD-GalCer, green) accumulated in the plasma membrane and to
a minor extent intracellularly. In parallel, intracellular colocalization ofTable 1
Liposome characterization.
Empty-L Dox-L
Size (nm) pdi Size (nm)
Standard-L 87.5 ± 2.1 0.05 ± 0.02 89.5 ± 1.1
C8-GlcCer-L 89.4 ± 1.4 0.05 ± 0.03 91.3 ± 1.2
C8-GalCer-L 88.4 ± 1.8 0.06 ± 0.01 89.4 ± 1.7
More than 3 independent batches were formulated for each formulation and each measuremeSC-GSL with lysosomes was performed. We observed a minor
colocalization of C6-NBD-GalCer (green) and lysotracker red, labeling
acidic organelles (Fig. 4).
3.5. SC-GSL transfer is tumor cell speciﬁc
The plasma membrane undergoes continuous rearrangements
through endo- and exocytosis. We studied the fate of C6-NBD-GalCer
in tumor and non-tumor cells and possible differences between those
cells in the handling of the SC-GSL. Liposomes containing the ﬂuores-
cent SC-GSL C6-NBD-GalCer were used to treat BLM melanoma cells,
3T3 ﬁbroblasts, and HUVEC endothelial cells, and the lipid fate was
followed in living cells for 14 h (Fig. 5A). Shortly after the start of treat-
ment, the ﬂuorescent SC-GSL analogue, C6-NBD-GalCer, accumulated
massively in the plasma membrane of BLM, melanoma cells. After 1 h
of incubation ﬂuorescence intensity reached a maximum and remained
constant throughout the 14 h time span of the experiment. BLM mela-
noma cells displayed little intracellular ﬂuorescence before liposome
treatment as a cellular background. During the 14h incubation, intracel-
lular ﬂuorescence increased suggesting lipid internalization and
processing. In contrast to BLM tumor cells, 3T3 and HUVEC cell incuba-
tionswith C6-NBD-GalCer resulted in lower levels of membrane uptake.
For non-tumor cells, C6-NBD-GalCer ﬂuorescence remained mainly
extracellular, most likely liposome associated.
3.6. Native SC-GSL transfer imaged by post-incubation click chemistry
Taking into account that the bulky NBD ﬂuorophore in the SC-GSL
could have a tremendous impact on the physicochemical features of
the lipid, we synthesized novel SC-GSL analogues as proof of concept
for the data obtained with ﬂuorescently C6-NBD-labeled SC-GSL. To
this end, ω-terminal alkyne-GSL analogues (cC8-GlcCer and cC8-
GalCer) were synthesized. The transfer and incorporation of SC-GSL
into the membrane of tumor vs. non-tumor cells were monitored by
click chemistry using the clickable SC-GLS (cSC-GSL) analogues
mentioned above. The extension of the transfer and respective incorpo-
ration of the lipid analogue into tumor and non-tumor cells was evalu-
ated based on the ﬂuorescence properties of the azide-labeled
ﬂuorophore, which labels, after alkyne-azide cycloaddition reaction,
the cell-associated c-SC-GSL lipid analogue.
When imaging cC8-GalCer (Fig. 6A) or cC8-GlcCer (Fig. 6B) after 2 h
at 37 °C, lipids transferred localized into distinct cell compartments
according to previous results with ﬂuorescent labeled lipid, C6-NBD-
GalCer, after cell washing. Strikingly, cC8-GalCer analogue was internal-
ized to a higher extent in tumor cells than in non-tumor cells. In
addition, the effect observed is much stronger that the observed with
cC8-GlcCer. Untreated cells were imaged using the same conditions as
SC-GSL-treated cells and displayed no Cy3-ﬂuorescent staining.
3.7. Lipid transfer quantiﬁcation in tumor and non-tumor cells
To quantify SC-GSL insertion into tumor vs. non-tumor cell
membranes, we initially performed a set of experiments in HeLa cells
in order to ﬁnd the right experimental conditions. As observed, incorpo-
ration into cell membranes is time and concentration dependent
(Fig. 7A). After 2 h at 37 °C, SC-GSL levels in cellmembraneswere higherpdi Loading (%) PL recovery (%)
0.06 ± 0.03 88 ± 2.0 68 ± 3.0
0.05 ± 0.04 86 ± 2.0 72 ± 2.0
0.07 ± 0.03 85 ± 1.0 73 ± 3.0
nt was performed in triplicate.
Fig. 2. Live cell confocal microscopy images of SKBR3 human breast carcinoma cells incubated with 20 μM liposomes containing the SC-GSL marker C6-NBD-GalCer (green) (A) for 2 h at
37 °C. Single cell-lipid transfer quantiﬁcation was performed by following the fate of C6-NBD-GalCer ﬂuorescence which increases signiﬁcantly in the cell membrane and is minor in cy-
toplasm, referring to a preferential lipid transfer to cellular membrane with higher accumulation in deﬁned plasma membrane areas (B). Movie 1 represents the lipid transfer from the
liposomes in suspension (green) and its massive accumulation in the cell membrane (red). Fluorescence intensity was quantiﬁed as described in Materials and methods section.
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concentration (in free form) from10 to 40 μM, increased cell membrane
associated SC-GSL levels (Fig. 7A).
Once the right experimental conditions are found, we next quantify
the SC-GSL insertion in tumor and non-tumor cells. Upon treatment of
BLM melanoma, MDAMB-231 breast carcinoma and 3T3 ﬁbroblast
cells with cSC-GSL (cC8-GalCer or cC8-GlcCer) added either in free
form (Fig. 7C) or co-inserted in liposome (Fig. 7D) incorporation of
the glycosphingolipids into the cells were quantiﬁed by TLC andﬂuores-
cence imaging. Following lipid extraction, the clickable analogue was
subjected to click chemistry reaction, and the amount of SC-GSLs
inserted into the different cells was quantiﬁed. As a reference, the initial
concentration of clickable SC-GSL added to the cells was loaded and
the ﬂuorescence value obtained was set to 100%. After normalization,BLM, and MDAMB-231 tumor cells showed higher incorporation of
cC8-GalCer or cC8-GlcCer than non-tumor ﬁbroblasts (p b 0.05)
(Fig. 7B). Similarly, when treating cells with liposomes containing cSC-
GSL, we observed a preferential incorporation of the lipid into tumor
cells in comparison to non-tumor cells (p b 0.05) (Fig. 7D). An illustra-
tion of the lipid measurement including the peaks of the covered lipid
area in different cell lines and respective TLC is represented in Fig. 7C.
3.8. SC-GSLs induce transbilayer redistribution (ﬂip-ﬂop) of pyr-SM in
model membranes
Under resting conditions, the diffusion of lipids across lipid bilayers
is very slow. Here we studied the effect of SC-GSL on transbilayer lipid
redistribution by using model membranes (Fig. 8). LUV's mimicking
Fig. 3. SC-SGL insertion into cellular membranes is a reversible process. Confocal microscopy imaging of ascending focal planes of BLM, melanoma cells incubated for 2 h at 37 °C with
medium (left-panel) or 60 μM C6-NBD-GalCer liposomes imaged before (central panel) and after washing (right panel).
Fig. 4. Live cell confocalmicroscopy images of SKBR3 human breast carcinoma cells incubatedwith 60 μMC6-NBD-GalCer (green) enriched liposomes and the lipophilic tracer DiDmarking
liposomes bilayer (blue). Colocalization study for C6-NBD-GalCer and lysotracker was performed incubating cells with red lysotracker for 1 h, washed and further incubated with lipo-
somes containing the SC-GSLs marker C6-NBD-GalCer. Intracellular colocalization of C6-NBD-GalCer and lysotracker was minor. Liposomes remained extracellularly, and C6-NBD-GalCer
accumulated at a high extent in the plasmamembrane. Cells were imaged with a 63× planachromat oil (n.a. 1.4) objective lens. Representative images of three independent experiments
are shown (n = 3).
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Fig. 5. (A) Time lapse live cell confocal microscopy of BLMmelanoma, 3T3 ﬁbroblast andHUVEC endothelial cells before treatment and at different time points after treatmentwith 60 μM
C6-NBD-GalCer liposomes for a total of 14 h. (B) Intensity of lipid ﬂuorescencewas quantiﬁed. For HUVEC, broken line represents absence of detected ﬂuorescence. Representative images
of three independent experiments are shown (n = 3).
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which inserts in the outer leaﬂet [26]. The lipid transbilayer diffusion
assay is based on the measurement of the intrinsic properties of the
ﬂuorescence pyrene-SM upon redistribution between the outer and
inner membrane monolayers. Here, pyr-SM was used to monitor the
transbilayer redistribution of the SM in the membrane induced by SC-
GSL (C8-GlcCer or C8-GalCer) and its clickable analogues (cC8-GlcCer
or cC8-GalCer). Both lipid analogues showed a similar extent of pyr-
SM ﬂip-ﬂop as their natural counterparts. Redistribution of the ﬂuores-
cent probe from the outer to the inner leaﬂet led to a decrease of the
excimer and an increase of the monomer concentrations. This reﬂects
a SM transbilayer distribution from the outer to the inner leaﬂet caused
by the addition of SC-GSL. Ethanol was used as negative control.
Addition of SC-GSL to LUVs caused 30% of SM transbilayer redistribu-
tion, 3-fold higher than the control (p = 0.0109).3.9. Formation of aqueous pores
To investigate whether drug-permeable domains formed by SC-GSL
represent physical aqueous pores, model membranes encapsulating
hydrophilic low molecular weight compounds were investigated for
possible SC-GSL-induced permeability. Membrane passage of hydro-
philic ANTS–DPX complexes upon incubation with SC-GSL-liposomes
was studied. These water-soluble complexes exist as a non-ﬂuorescent
complex when entrapped in the LUV's core. Upon the formation of a
hydrophilic pore, vesicle efﬂux occurs, causing dilution of the complex
and subsequent ANTS–DPX dissociation, which can be assessed by
measuring ANTS ﬂuorescence (Fig. 9). 100% leakage of ANTS–DPX was
set by total disruption of LUV's in the presence of detergent. Incubation
of C8-GalCer or C8-GlcCer liposomes with ANTS–DPX entrapped in LUVs
did not display changes in ﬂuorescence demonstrating that ANTS
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tetanolysin, a cholesterol-binding dependent toxin was used to create
pores in the bilayer. Based on these results, transient pore formation
induced by SC-GSL is excluded as a possible mechanism used by SC-
GSL to boost drug binding and uptake in cells.
3.10. Inﬂuence of temperature on function of SC-GSL as intracellular drug
uptake enhancers
To address the mechanism of SC-GSL as drug uptake enhancers, SC-
GSL enriched liposomes containing Dox were used to treat MDAMB-231Fig. 6. Confocal imaging of ﬂuorescently labeled cSC-GSL incorporation into tumor cells (BLMm
treated with 10 μM of either cC8-GalCer (A) or cC8-GlcCer (B) for 2 h were ﬁxed and subject
performed with Hoechst (blue) and WGA 488 (green), respectively. Representative images ofbreast carcinoma and BLM melanoma cells. Using the autoﬂuorescent
properties of Dox, intracellular drug uptake was followed by confocal mi-
croscopy and drug uptake levels of SC-GSL-enriched liposomes (GalCer-
DoxL) were compared to standard liposomes (Dox-L) without SC-GSL
and free drug. Cellular incubation at 4 °C causes a more laterally ordered
lipid bilayer and increases cell membrane rigidity [34]. It also inhibits
energy-dependent drug transport across the cellmembrane. Doxwas im-
aged in MDAMB-231 or BLM cells by live cell confocal microscopy after
2 h of incubation at 4 °C before and after washing (Fig. 10 left panels).
After imaging, cells were further incubated for 2 h at 37 °C, and then im-
aging before and after washing was performed (Fig. 10 right panels).elanoma andMDAMB-231 breast carcinoma) and non-tumor cells (3T3 ﬁbroblasts). Cells
ed to click reaction with Cy3-azide (red). Nuclear and plasma membrane staining were
three independent experiments are shown (n = 3).
Fig. 6 (continued).
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ma and BLMmelanoma cells at 4 °C. A signal from free Dox is visible as a
reddish background in the extracellular space.More abundantDox ﬂuo-
rescence is found to be associated with MDAMB 231 and BLM cells are
incubated with SC-GSL enriched Dox-liposomes (GalCer-L) at 4 °C.
Treatment with standard liposomes at 4 °C results in hardly detectable
intracellular drug levels, and Dox signal is almost entirely lost after
washing, indicating that the ﬂuorescent signal before washing resulted
frommembrane-associated drug. After an additional incubation at 37 °C
for 2 h (third column), both cell lines showed nuclear uptake of free
Dox. Most of Dox signals remain after washing conﬁrming intracellular
presence, especially in the nucleus, whereas some cytoplasmic ormembrane-associated Dox is also removed upon washing. After the
treatment with SC-GSL-enriched liposomes for 2 h at 4 °C and 2 h at
37 °C, Dox is found to be intracellular in the nucleus as well as cytoplas-
mic and membrane-associated. Following washing, the cytoplasmic/
membrane-associated drug fraction is almost entirely removed from
cells, and intracellular Dox is naturally directed to the nucleus where
it exerts its cytotoxic action. At 37 °C, when cells were treated with
GalCer-DoxL, Dox reached the nucleuswhere it is retained. For standard
liposomes, cytoplasmic, nuclearDox uptake isminimal and ismainly cy-
toplasmic or membrane bound.
Finally, the effect of SC-GSL on intracellular Dox uptake was quanti-
ﬁed by ﬂow cytometry in tumor BLM, melanoma and non-tumor 3T3
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hanced intracellular drug levels in comparison to standard liposomes
and preferentially in tumor cells (**p b 0.01) (Supplemental Fig. 2).
4. Discussion and conclusion
Our initial working hypothesis is based on a spontaneous transfer of
the SC-GSL from the liposomal bilayer to the cell membrane, leading to
cell membrane permeability modiﬁcations and subsequent enhancing
of intracellular amphiphilic drug inﬂux. This mechanism suggests a
novel possible way to improve therapeutic efﬁcacy of applied cytostatic
drug in cancer treatment [15,16,18]. Here, we investigated the molecu-
lar mechanism of action underlying liposomal SC-GSL as cellular drug
uptake enhancer.
In this studywewere able to demonstrate that upon cellular contact
SC-GSLs are spontaneously transferred from the liposomal bilayer to the
plasmamembrane,most likely into the exoplasmatic leaﬂet (Fig. 2, Sup-
plemental Fig. 1) where Dox membrane interaction and transmem-
brane transport are facilitated [30]. To validate the results obtained
with the ﬂuorescent analogue NBD-GalCer (Fig. 2A), which ﬂuorophore
is known to change the biophysical, trafﬁcking andmetabolical featuresFig. 7. Lipid transfer quantiﬁcation in tumor versus non-tumor cells. (A) cC8-GlcCer lipid analog
lipid analogue insertion into plasma membranes was quantiﬁed by click chemistry. Lipid trans
than in non-tumor cells. SC-GSL transfer to the plasmamembrane was quantiﬁed by TLC in fre
independent experiments were performed. Results of unpaired, two-tailed t-test are given: *p≤
tion running correspond to duplicates of the experiments.of the lipid in some cases, we designed and synthesized novel SC-GSL
analogues. These new molecules have a ω-terminal alkyne for click
chemistry reaction with a ﬂuorescently labeled azide. Using these
novel cSC-GSLs (cC8-GlcCer or cC8-GalCer), it was possible to follow
the fate of the lipidwithout interferingwith its original and native struc-
ture. SC-GSL transfer occurred mainly in intracellular compartments at
higher extension in tumor cells, and its intracellular accumulation was
found to be concentration dependent (Figs. 6 and 7). The ﬂuorescently
labeled SC-GSL analogue C6-NBD-GalCer inserted in the liposomal bilay-
er (Fig. 2A) is transferred and re-distributed throughout the plasma
membrane with seemingly increased levels in ﬁlopodia or lamellopodia
like cellular protrusions (Fig. 2B, Movie 1). Such particular structures
were only observed in cells treated with SC-GSL enriched liposomes,
conﬁrming a close contact between particles and cells, which supports
short-chain GSL transfer and subsequently plasmamembrane structure
destabilization (Supplemental Fig. 1). Biomembranes are non-
equilibrium structures, in which lipid asymmetry is maintained by ac-
tive transbilayer lipid transport [31,32]. When lipid transfer occurs in
one direction, it is naturally compensated by the simultaneous transfer
of (the same or) other lipids in the reciprocal direction so thatmass con-
servation in each monolayer is maintained. The opposite situation,ue insertion is concentration and exposure time dependent. (B) cC8-GalCer or cC8-GlcCer
fer in tumor cells was signiﬁcantly (*)(p b 0.05) or very signiﬁcantly (**)(p b 0.01) higher
e form (C) or liposome co-inserted (D). Control was set as 100% of initial lipid amount. Six
0.05 or **p b 0.01 in comparison to 3T3, ﬁbroblasts. Twin numbers under the lipid extrac-
Fig. 7 (continued).
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lateral pressure and bilayer collapsing. It is also known that the
maintenance of membrane asymmetry in the resting state is energy
dependent, and that ﬂip-ﬂop of lipids cannot occur by itself [32].
Transbilayer lipid motion triggered by external agents has been
shown only for long-chain ceramides [20]. Here, we have demonstrated
a highly efﬁcient transbilayer lipid movement or ﬂip-ﬂop by external
glycosylated short-chain glycosylceramides, C8-GlcCer or C8-GalCer
(Fig. 8). Moreover, the transbilayer lipid movement from the outer to
the inner leaﬂet measured in this work with SC-GSL is higher than the
previously described with short-chain ceramides (C6 or C2-ceramide)
by our group [20]. This points to a different molecular mechanism of
action for SC-GSLs, where the sugar head group could play a major
role in the formation and stabilization of transitory membrane
nanopore, which facilitates lipid ﬂip-ﬂop and cellular drug uptake.
Finally, the ability of cC8-Glc-Cer and cC8-GalCer to induce a similarextent of ﬂip-ﬂop in model membranes compared to natural ones
proves that the physicochemical properties of the analogues are very
close to their natural counterparts (Fig. 8).
External addition of SC-GSL like C8-GlcCer or C8-GalCer [33,34]
might induce membrane lipid rearrangement, when self-associating
or interactingwith natural lipids (i.e. cholesterol, sphingolipids) present
in the outer leaﬂet of the plasma membrane facilitating lipid microdo-
main formation and membrane permeability. It has been described
that N-acyl long chain (more than 12 °C) ceramides but not N-acyl
short-chain ceramides were able to induce the formation of stable
lipid microdomains [35]. Here, possible pore domain formation, similar
to the described with ceramides, induced by SC-GSL transfer to model
membranes was also studied (Fig. 9). The results obtained did not
show a leakage of hydrophilic compounds, conﬁrming previously
reported data by co-workers in cellular studies [14], where it was
shown that C6-SM does not increase membrane permeability of a
Fig. 8. Short-chain GSLs induced transbilayer movement of pyr-SM in plasma membrane
like LUVs. The original lipid concentration was 300 μM. The following additions were
made to 1 ml of the LUV suspension at time 0: 15 μM C8-GlcCer in 2 μl of ethanol (■),
15 μM C8-GalCer in 2 μl ethanol (▲), 15 μM cC8-GlcCer in 2 μl ethanol (○), 15 μM cC8-
GalCer in 2 μl ethanol ( ), and 2 μl ethanol (●). Average values± SD (n=3). Results of un-
paired, two-tailed t-test are given: **p ≤ 0.01.
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[15]. Possibly, SC-GSL induces the rearrangement of the cell membrane
enhancing intracellular drug uptake by processes that do not include
aqueous pore domain formation.
It has been described that a sugar moiety in the polar head group
weakens intermolecular interactions by reducing packing efﬁciency
[36]. In the case of glycosylsphingolipids, such as C8-GlcCer and C8-
GalCer (containing relatively small polar head groups) the increase of
molecular order acquired by close packing is unfavorable because it
cannot be compensated by release of enough molecules of water from
the polar head group hydration shell [36]. Partly, this supports the
rearrangement of the plasma membrane structure by the transfer of
SC-GSLs (Fig. 8) with increased permeability to drug traversal
(Fig. 10, Supplemental Fig. 2). SC-GSL insertion in the cell membrane
might lower packing density, promoting Dox insertion and Dox–SC-
GSL interaction [17] or enhancing exposure Dox to binding lipids
(e.g. PE) in the plasma membrane improving intracellular drug
uptake [37].Fig. 9. Time course of SC-GSLs induced efﬂux of ANTS/DPX. 15 μM of C8-GalCer (blue) or
C8-GlcCer (red) was externally added to freshly prepared plasma membrane like LUVs
(300 μM), and ANTS/DPX efﬂux monitored over time. Ethanol (2 μl) and tetanolysin
(10 ng) were used as negative and positive controls, respectively. Representative image
of three independent experiments are shown (n = 3).SC-GSL-plasma membrane transfer was found to be reversible as
observed after extensive cell washing (Fig. 3). These ﬁndings suggest
that SC-GSLs accumulate to a large extent in the outer leaﬂet of the
PM. Whereas lipid transfer to the plasma membrane occurred substan-
tially, this occurred without intracellular uptake of the liposomes
(Fig. 4) which conﬁrms previous data on enhanced drug uptake by
non-ﬂuorescently labeled-SC-GSL enriched liposomes containing Dox
in MCF-7 breast carcinoma cell line [18]. Besides a massive transfer to
the plasma membrane (Fig. 2B, Movie 1 — red) part of the lipid
remained associated with the liposomal bilayer (Movie 1 — green).
The transfer phenomenon occurs from ﬁlled to empty SC-GSL
membranes, a concentration gradient that requires only SC-GSL
enriched liposome versus plasmamembrane contact. Althoughmassive
membrane accumulation was observed for prolonged periods (Fig. 3),
intracellular presence of C6-NBD-GalCer was found although in a
minor extent, especially after extensive washing, which removed the
majority of membrane-associated SC-GSLs (Figs. 3 and 4). Live cell
imaging with C6-NBD-GalCer (Fig. 5) and click chemistry lipid quantiﬁ-
cation (Fig. 7) in free and liposomal forms of tumor and non-tumor cells
demonstrated a preferential transfer and incorporation of SC-GSLs into
tumor cell membranes (Fig. 7B, C, D). This result conﬁrms earlier obser-
vations showing that the drug uptake enhancing properties of SC-GSLs
and subsequent induction of cytotoxicity are much more speciﬁc for
various tumor cell lines and much less for normal cells [15,16,18,29].
By preferentially targeting the tumor cell membrane (Figs. 5, 7) and
modulating its permeability to drug uptake (Fig. 10, Supplemental
Fig. 2) [18,29], SC-GSLs represent a promising possibility to improve
chemotherapy efﬁcacy. In addition, live cell imaging and co-staining
with lysotracker conﬁrmed minor lysosomal localization of C6-NBD-
GalCer (Fig. 4). Lipidome analysis of tumor and non-tumor cells shows
a distinguished phospholipid pattern mainly at the level of phosphati-
dylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine,
sphingomyelin (SM) and phosphatidylinositol (PI) [38]. Differences in
phospholipid patterns are described to decrease membrane permeabil-
ity of tumor cells by an increased rigidity and promote tumor progres-
sion [17,38]. Recently, it has been reported that faster-proliferating
cells modulate and rearrange their lipidome [39] supporting the differ-
ential phospholipid composition between tumor and non-tumor cells.
In addition, lower cholesterol levels are described to increase mem-
brane ﬂuidity in tumor cells [17,38]. The lipidome of tumor cells is
also associated with multidrug resistance phenomenon inﬂuencing
the ability of tumor cells to respond to chemotherapy [40]. Likely the
speciﬁc cellular lipidome determines the afﬁnity for SC-GSL membrane
insertion and subsequently causes enhanced drug uptake speciﬁcally in
tumor cells (Figs. 5, 7, Supplemental Fig. 2).
The process by which Dox normally crosses the plasma membrane
involves spontaneous adsorption by insertion of the molecule's hydro-
phobic anthraquinone into the exoplasmic leaﬂet of the lipid bilayer,
followed by an energetically unfavorable ﬂip-ﬂop of the drugs' hydro-
philic sugarmoiety between the outer and the innermembrane leaﬂets.
At physiological conditions, this ﬂip-ﬂop is extremely slow with a half-
life of 0.7 min [30]. The cellular uptake of free Dox at 4 °C (Fig. 10) is
therefore virtually impossible for thermodynamic reasons. Themarginal
signal of free Dox at 4 °C in Fig. 10 hence results from membrane-
associated Dox molecules, but Dox transmembrane transport does not
occur and no uptake of free Dox occurred at 4 °C neither in MDAMB
231 nor in BLM tumor cells. Comparing the results from Figs. 4 with
10 reveals that Dox ﬂuorescence in Fig. 10 is originated from Dox in
the free and not liposomal form since liposomes are not taken up
and so remain extracellular. Membrane-associated Dox can easily be
washed away, explaining complete loss of ﬂuorescent signal afterwash-
ing cells treated with free Dox at 4 °C. In addition cells treated with Dox
in form of SC-GSL enriched liposomes show an intense signal for
membrane-associated Dox even at 4 °C with the transmembrane
transport blocked. Washing reveals that Dox is mostly membrane co-
associated with SC-GSL. At 4 °C, the presence of SC-GSL in the liposome
Fig. 10. Temperature-dependent intracellular Dox uptake in MDAMB-231 carcinoma cells (A) and BLMmelanoma cells (B). Imaging of cells treated with either 40 μM of GalCer-DoxL or
Dox-L or free Dox incubated at 4 °C for 2 h or at 4 °C for 2 h and immediately at 37 °C for 2 h were taken before (left panel) and after washing (right panel), respectively. Red ﬂuorescence
represents Dox. Representative image of three independent experiments are shown (n = 3).
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compared to non-enriched liposomes. This suggests that at 4 °C, SC-
GSLs exert their effect on the outer membrane leaﬂet. At 4 °C, the
reducedmembrane ﬂuidity leads to stabilization of lipid microdomains,
blocking intracellular transport and perhaps slowing down the ﬂip-ﬂop
process. After additional incubation at 37 °C for 2 h, of MDAMB 231 or
BLM cells, intracellular uptake of Dox delivered as free drugwas compa-
rable toDox delivered fromSC-GSL enriched liposomes,whereas uptake
of non-enriched liposomes is marginal (Fig. 10, Supplemental Fig. 2).
Here, we conclude that SC-GSLs exert their effect on the outer mem-
brane leaﬂet, where they enhance the Dox–membrane inﬂux by a
biophysical process and consequently facilitate Doxmembrane travers-
al. Considering the easywashing of Doxmolecules at 4 °C and of SC-GSL
molecules as observed in Fig. 3, we may speculate on the association of
Dox molecules to SC-GSL at the level of the outer leaﬂet without
interference with cellular mechanisms. This is supported by modeling
experiments by Van Hell and coworkers, who reported molecular
assembly of SC-GSL and Dox when the latter associates to the
hydrophobic core of the bilayer [17].
In summary, important insights into the mechanism by which SC-
GSL enhance drug uptake are described. SC-GSL can transfer spontane-
ously to the plasmamembrane preferentially in tumor cells modulating
plasma membrane permeability to cytostatics drugs, therefore enhanc-
ing its inﬂux and efﬁcacy. Moreover, membrane-restructuring effects
within the plasma membrane induced by SC-GSL were determined
as the driven role for enhanced intracellular drug inﬂux. This
mechanism, besides representing an exciting tool to improve the
speciﬁc targeting of tumoral cells, might also reverse chemotherapy
resistance.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2015.04.011.Transparency document
The Transparency document associated with this article can be
found, in the online version.
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